Skip to content

Looking for what’s NEXT in contraception? New course available now

Combined oral contraceptive (COC) pills are one of the most frequently dispensed medications in pharmacy, and little has changed in this space over the years. Despite this, COC pills can be overwhelming, and potentially high-risk medications to dispense due to the different combinations and doses of estrogens and progestogens. In fact, COCs featured on the Pharmaceutical Defence Limited (PDL) list of top 10 drugs in incident reports in August 2022.

In 2023, pharmacists are presented with a new option in the COCs space, NEXTSTELLIS, a combination of a low-impact, natural estrogen with unique selective activity (estetrol, E4) and drospirenone. This represents a significant change in the COC landscape. 

To assist pharmacists to better understand the new landscape, and reduce confusion between the available combinations, GuildEd and the Australasian College of Pharmacy are pleased to announce the availability of a new course titled “NEXTSTELLIS® (estetrol/drospirenone) Looking for what’s NEXT in contraception?”

In this course we will discuss the evolution of COC pills, considerations when selecting a COC pill, the benefits of a low-impact, natural estrogen, and identify patients that may benefit from NEXTSTELLIS. This course also describes limitations for prescribing NEXTSTELLIS in certain groups and discuss the role of the pharmacist in ensuring the appropriate use of NEXTSTELLIS as a new product on the market.  

GuildEd in partnership with the Australasian College of Pharmacy would like to thank Mayne Pharma, distributor of NEXTSTELLIS for their financial assistance and subject matter expertise in developing this module. 


This activity has been accredited for 1 hr of Group 1 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hr of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities. Click here to access the course:

Share this article:

Articles you might be interested in

Scroll To Top